```html

Uterine Arteriovenous Malformation (AVM): A Comprehensive Patient Guide

Overview

An uterine arteriovenous malformation (AVM) is a rare, abnormal connection between arteries and veins within the uterus. Instead of passing through the normal capillary network, blood flows directly from high‑pressure arteries into low‑pressure veins, creating a tangle of fragile vessels that can bleed heavily.

Uterine AVMs are most often diagnosed in women of reproductive age, typically between 20 and 45 years, but cases have been reported in adolescents and post‑menopausal women. The exact prevalence is difficult to determine because many cases are discovered incidentally during imaging for unrelated pelvic pain or abnormal bleeding. Epidemiologic studies estimate an incidence of roughly 0.1–0.5 per 100,000 women per year (Mayo Clinic Proceedings, 2020).

Although uterine AVMs are benign (non‑cancerous), their tendency to cause profuse vaginal bleeding can be life‑threatening if not promptly recognized and treated.

Symptoms

Symptoms vary according to the size of the malformation and whether it is hormonally active. Common presentations include:

• Heavy or prolonged vaginal bleeding – often described as “menstrual bleeding that doesn’t stop” or bleeding that occurs between periods.
• Post‑procedural bleeding – excessive bleeding after a dilation & curettage (D&C), endometrial biopsy, hysteroscopy, or childbirth.
• Pain or pelvic pressure – a dull, cramp‑like discomfort that may worsen during menstruation.
• Spotting or brown discharge – especially after sexual intercourse (post‑coital bleeding).
• Rapid drop in hemoglobin – may cause fatigue, shortness of breath, or dizziness.
• Infertility or recurrent miscarriage – the abnormal blood flow can interfere with implantation.
• Incidental finding – some AVMs are discovered on ultrasound or MRI performed for unrelated reasons.

If bleeding is sudden and massive, it can lead to hypovolemic shock, a medical emergency that requires immediate attention.

Causes and Risk Factors

Uterine AVMs are classified as either congenital (present at birth) or acquired. The majority are acquired.

Acquired causes

• Prior uterine surgery – D&C, hysteroscopic polypectomy, myomectomy, or cesarean section can damage blood vessel walls.
• Gestational trophoblastic disease – conditions such as molar pregnancy increase vascular remodeling.
• Uterine trauma – severe pelvic injury or uterine perforation.
• Endometrial hyperplasia or carcinoma – abnormal tissue growth can stimulate angiogenesis.

Congenital factors

• Developmental errors in the embryologic formation of the uterine vasculature.
• Associated with rare genetic syndromes (e.g., hereditary hemorrhagic telangiectasia) that predispose to AVMs elsewhere in the body.

Risk factors

• History of uterine surgery or curettage.
• Previous episodes of heavy menstrual bleeding of unknown cause.
• Pregnancy complications, especially molar pregnancy.
• Age 20‑45 (peak reproductive years).
• Smoking – may impair vascular integrity.

Diagnosis

Because uterine AVM can mimic other sources of abnormal bleeding (fibroids, polyps, cancer), a systematic work‑up is essential.

Initial evaluation

• History and physical exam – detailed menstrual and surgical history; pelvic examination for uterine size or tenderness.
• Laboratory tests – CBC to assess anemia, coagulation profile, pregnancy test (to rule out pregnancy‑related bleeding).

Imaging studies

1. Transvaginal color Doppler ultrasound – first‑line test. AVMs appear as a heterogeneous, “turbulent” vascular mass with high‑velocity, low‑resistance flow (peak systolic velocity > 30 cm/s).
2. Pelvic MRI with contrast – provides detailed anatomy, especially useful when ultrasound is inconclusive or the lesion is deep.
3. Computed tomography angiography (CTA) – maps feeding arteries and draining veins; often employed before embolization procedures.
4. Digital subtraction angiography (DSA) – gold standard; allows real‑time visualization and therapeutic intervention (embolization) in the same session.

Differential diagnosis

Conditions that can mimic AVM on imaging include retained products of conception, uterine fibroids with cystic degeneration, endometrial polyps, and gestational trophoblastic disease. Accurate diagnosis hinges on the characteristic high‑flow Doppler signal.

Treatment Options

Management is individualized based on the patient’s age, desire for future fertility, size of the AVM, and severity of bleeding.

Conservative/Medical management

• Hormonal therapy – combined oral contraceptives, progestin‑only pills, or GnRH agonists can reduce menstrual flow and may shrink small AVMs, but evidence is limited.
• Tranexamic acid – an antifibrinolytic that can help control acute bleeding episodes (short‑term use only).

Medical therapy alone is rarely curative and is generally reserved for patients who are poor surgical candidates or who wish to attempt fertility preservation before definitive treatment.

Minimally invasive procedures

1. Uterine artery embolization (UAE) – the most common definitive treatment. Under fluoroscopic guidance, tiny particles are injected to block the feeding arteries, causing the AVM to thrombose. Success rates range from 80‑95% (Cleveland Clinic).
2. Selective arterial catheter‑based laser or radiofrequency ablation – emerging techniques for very small lesions.

Surgical options

• Hysteroscopic resection – for focal, superficial AVMs confined to the endometrial cavity; requires experienced operators.
• Myomectomy or local excision – if the AVM is intramural and well‑demarcated.
• Hysterectomy – definitive cure for women who have completed childbearing or when bleeding cannot be controlled by less invasive means.

Post‑procedure care

• Bed rest for 24 hours after embolization.
• Serial hemoglobin checks to ensure bleeding control.
• Avoidance of high‑impact exercise for 2‑3 weeks.
• Follow‑up Doppler ultrasound at 1‑3 months to confirm resolution.

Living with Uterine AV Malformation

Even after successful treatment, patients may need ongoing monitoring and lifestyle adjustments.

• Track menstrual patterns – note any return of heavy bleeding or spotting and report to your clinician.
• Maintain adequate iron intake – through diet (red meat, leafy greens, legumes) or supplements if labs show low ferritin.
• Regular follow‑up imaging – once yearly for the first two years, then as directed.
• Exercise safely – low‑impact activities (walking, swimming) are encouraged; avoid heavy lifting that raises intra‑abdominal pressure during the early post‑procedure period.
• Sexual health – most women can resume intercourse after 2‑3 weeks post‑embolization or surgery, but discuss any pain or bleeding with your provider.
• Pregnancy counseling – if you become pregnant after UAE, there is a small risk of recurrence or placental abnormalities; close obstetric monitoring is essential.

Prevention

Since many AVMs are acquired, certain practices can lower the risk of developing this vascular anomaly:

• Limit unnecessary uterine instrumentation – choose medical management for early pregnancy loss when appropriate.
• When curettage or hysteroscopic procedures are needed, ensure they are performed by experienced clinicians using gentle techniques.
• Quit smoking – improves overall vascular health.
• Promptly treat and follow up gestational trophoblastic disease to reduce abnormal angiogenesis.
• Maintain a healthy weight and control hypertension, which can stress blood vessel walls.

Complications

If left untreated, uterine AVM can lead to serious health issues:

• Severe hemorrhage – may require blood transfusion, intensive care, or emergency hysterectomy.
• Iron‑deficiency anemia – chronic blood loss causing fatigue, decreased exercise tolerance, and impaired cognitive function.
• Infertility – due to distorted uterine lining or recurrent bleeding.
• Recurrent pregnancy loss – vascular instability can disrupt implantation.
• Psychological impact – anxiety or depression related to unpredictable bleeding episodes.

When to Seek Emergency Care

Key Take‑aways

• Uterine AVM is a rare but potentially dangerous vascular lesion that most often presents with heavy or prolonged uterine bleeding.
• Accurate diagnosis relies on color Doppler ultrasound and, when needed, angiographic studies.
• Uterine artery embolization is the first‑line definitive therapy for most women; hysterectomy remains an option for those who have completed childbearing or when bleeding cannot be controlled.
• Regular follow‑up, iron management, and lifestyle measures are essential for long‑term health.
• Any sudden, massive bleeding warrants immediate emergency care.

For personalized advice, always discuss your symptoms and treatment options with a gynecologist or interventional radiologist. Information in this guide is based on current evidence from reputable sources such as the Mayo Clinic, CDC, NIH, WHO, and Cleveland Clinic.

```